Women's Health

The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.

What can we help you find?
[[thumbnail_alt_text]]
Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
[[thumbnail_alt_text]]
The action requires the company to revise safety information that women and their health care professionals need when considering use of the drug.
[[thumbnail_alt_text]]
Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.
[[thumbnail_alt_text]]
This therapy is expected to become available in late June.
[[thumbnail_alt_text]]
Indicating for preventing pregnancy, a statement from the FDA said that loss of efficacy is possible if the user misses tablets. 
 
[[thumbnail_alt_text]]
Many women are unaware of HIV pre-exposure prophylaxis (PrEP) but show a keen interest in spreading the word once they learn about the option, according a recent study in the journal Contraception.
[[thumbnail_alt_text]]
A survey of sexually active women in the United States revealed that 29% experienced challenges in obtaining either a prescription or a refill for hormonal contraception.
[[thumbnail_alt_text]]
Researchers at Kaiser Permanente Washington conducted a qualitative pilot study to understand the experiences and decision-making women face as they contemplate the use of antinausea medications during pregnancy.
[[thumbnail_alt_text]]
Using a drug that increases GABA synthesis and possibly escalates intraneuronal dopamine in a population that is more likely to have behavior health concerns may prove to be an unsafe option.
[[thumbnail_alt_text]]
Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and MSD) for the maintenance treatment of adult patients with BRCA-mutated advanced ovarian cancer.
[[thumbnail_alt_text]]
Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.
[[thumbnail_alt_text]]
Can you solve the pharmaceutical mystery? Each week, a new case study is presented.